Educational only. Not medical advice. Invite-only research preview.No PHI. Do not share patient names or identifying information (HIPAA).
MytoIntelligence
All targets

Molecular target

Calcineurin (PP2B)

Calcium-dependent phosphatase activating NFAT transcription factor — central to T-cell activation. Inhibition (cyclosporine, tacrolimus, voclosporin) is the foundation of solid-organ transplant immunosuppression. Both drugs are CYP3A4 substrates with extensive interaction profiles relevant to many botanical CYP modulators.

4 drugs act here1 plant reach it via their compounds

Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.

No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.

Pharmaceutical agents

Drugs that act on Calcineurin (PP2B)

These medications have Calcineurin (PP2B) among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.

Botanical connections

Plants whose compounds act on Calcineurin (PP2B)

Each plant below contains a named compound documented to act on Calcineurin (PP2B). The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.

  • Cyclotides (e.g. varv A, varv E, cycloviolacin series)Macrocyclic cystine-knot peptides

    In vitro studies report inhibition of T-cell proliferation, potentially via calcineurin-dependent pathways, and suppression of pro-inflammatory cytokine release; structural resistance to enzymatic degradation is considered pharmacologically relevant in lead-molecule research.

A shared molecular target shows how a botanical and a drug relate mechanistically. It is not evidence that one can replace the other. Educational summary only — discuss any medication decision with your clinician.